Sensus Healthcare Inc. has announced a strategic partnership with Radiology Oncology Systems (ROS) to expand the distribution of its superficial radiotherapy $(SRT)$ systems in the U.S. oncology market. This agreement designates ROS as the primary distribution partner for Sensus's SRT systems, including the SRT-100™ and SRT-100 Vision™, targeting hospital-based and freestanding oncology centers nationwide. The collaboration aims to increase the adoption of Sensus's non-invasive radiotherapy technologies, recognized for their effective aesthetic outcomes and minimal disruption to clinical workflows. Initial product orders are anticipated by the fourth quarter of 2025, with prospects for international market expansion in the future.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.